Skip to main content
. Author manuscript; available in PMC: 2016 Oct 16.
Published in final edited form as: ACS Chem Biol. 2015 Jul 30;10(10):2267–2276. doi: 10.1021/acschembio.5b00265

Figure 7.

Figure 7

Compound 1 impeding tumor growth in vivo at a lower effective dose than a synthetic miR-544 antagomir. (a and b) Live bioluminescent imaging of NOD/Scid mice at 3 weeks postimplant of MDA-MB-231-GFP-luc cells. Images show mice administered GFP-labeled tumor cells that were pretreated with 1 or miR-544 antagomir in vitro prior to transplantation (a) or were administered an IP injection of 1 or antagomir 24 h postimplantation of tumor cells (b). (c) Images of MDA-MB-231-GFP-luc/Matrigel tumor masses resected from untreated, 1-treated, or miR-544 antagomir-treated mice 21 days after IP treatment injection. (d and e) Real-time qPCR analysis of hypoxia-associated gene transcripts (d) and miR-544 precursor and mature transcripts (e) in tumor samples resected from NOD/Scid mice from b. *, p < 0.05.